Vimpat available soon for partial-onset seizures Vimpat (lacosamide, from UCB), an antiepileptic drug (AED), will be available the first week of June 2009. Vimpat tablets are indicated as ...

It is the fourth most common neurological disorder in the U.S. With the approval of the supplemental new drug application (sNDA) for Vimpat, the drug’s label now covers three treatment options ...

ATLANTA, June 14, 2010 /EurekAlert/ -- UCB today announced the availability of an oral solution formulation of Vimpat® (lacosamide) C-V, an antiepileptic drug (AED) for add-on treatment of ...

ATLANTA, Nov. 30, 2010 /PRNewswire/ -- New data on UCB's anti-epileptic drug (AED) Vimpat® (lacosamide) C-V will be presented at the 64th annual meeting of the American Epilepsy Society (AES ...

Pfizer’s Lyrica Is The Top Selling Anti-Epileptic Drug, Followed By UCB’s Vimpat, and Keppra. Pfizer’s Lyrica sales have been in the range of $4.8 to $5.2 billion over the last 5 years.

ATLANTA An investigational drug can reduce seizures in adolescents ... found that UCB’s Vimpat (lacosamide) resulted in “significantly” fewer partial-onset seizures in patients ages 16 ...

Vimpat Gains Monotherapy Indication for Seizures UCB announced that the Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for Vimpat (lacosamide ...

UCB has filed for US approval of the monotherapy use of its epilepsy drug Vimpat. The drug has been available since 2008 as an adjunctive, or supplementary, treatment for partial-onset seizures in ...

Pfizer’s Lyrica Is The Top Selling Anti-Epileptic Drug, Followed By UCB’s Vimpat, and Keppra. Pfizer’s Lyrica sales have been in the range of $4.8 to $5.2 billion over the last 5 years.